SV40 and p53 as team players in childhood lymphoproliferative disorders.

Standard

SV40 and p53 as team players in childhood lymphoproliferative disorders. / Heinsohn, Susanne; Scholz, Roswitha; Kabisch, Hartmut.

In: INT J ONCOL, Vol. 38, No. 5, 5, 2011, p. 1307-1317.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Heinsohn S, Scholz R, Kabisch H. SV40 and p53 as team players in childhood lymphoproliferative disorders. INT J ONCOL. 2011;38(5):1307-1317. 5.

Bibtex

@article{7cf847c7ebe5432199ada5433b1d81fe,
title = "SV40 and p53 as team players in childhood lymphoproliferative disorders.",
abstract = "Simian virus 40 (SV40) is known to be potently oncogenic and can induce several types of tumours, such as lymphoma. p53 was discovered as a cellular partner of the SV40 large T-antigen, the oncoprotein of this virus. There have not been many studies on SV40 and p53 in lymphomas and the ones that exist, are controversial. A comparison of these two components in lymphoma has not been reported previously. We examined 91 lymphomas [60 B-cell non-Hodgkin's lymphomas (B-NHLs), 19 B-cell acute lymphoblastic leukemias (B-ALLs), 7 B-cell precursor acute lymphoblastic leukemias and 5 T-cell acute lymphoblastic leukemias] for the presence of SV40. Overall, 40 samples from 12 B-NHL/19 B-ALL patients were additionally investigated for p53 mutation in the hot-spot exons 5 to 8. Overall, we found 62/91 lymphomas to be SV40-positive, among them 16/19 B-ALLs and 38/60 B-NHLs. SV40 was absent in 147 of the 149 blood control samples. We found 11 p53 mutations in 19 B-ALL patients: 5 in exon 5 (codons 132, 141, 143, 155 and 181), 4 in exon 7 (codons 236, 238 and 248), 2 in exon 8 (codon 273). In B-NHL patients we found p53-mutations in 9/12 samples: 6 of these in 3 lymph nodes (LNs). One LN harboured 3 different p53 mutations: Exon 5 (codon 132), exon 6 (codon 213) and exon 8 (codon 288). Another LN showed 2 different p53 mutations: Exon 6 (codon 213) and exon 8 (codon 285). Except for 1 nonsense mutation in an LN of a B-NHL patient, all 20 mutations were missense mutations, 2 were homozygous, both found in B-NHL-samples, and one of these (codon 175) is known to cause the global denaturation of p53. All occur in the DNA-binding domain of p53. All specimens showing a p53 mutation, were SV40-positive. p53 mutaions found in LNs of B-NHL patients harbour high SV40 copy numbers. Our data strongly support an important role for SV40, as well as a strong association of SV40 and p53 in childhood lympho-proliferative disorders.",
keywords = "Animals, Humans, Adolescent, Child, Child, Preschool, Infant, Infant, Newborn, COS Cells, Cercopithecus aethiops, Exons, *Mutation, Genes, p53/*physiology, Lymphoproliferative Disorders/*etiology/genetics/virology, Simian virus 40/*isolation & purification, Animals, Humans, Adolescent, Child, Child, Preschool, Infant, Infant, Newborn, COS Cells, Cercopithecus aethiops, Exons, *Mutation, Genes, p53/*physiology, Lymphoproliferative Disorders/*etiology/genetics/virology, Simian virus 40/*isolation & purification",
author = "Susanne Heinsohn and Roswitha Scholz and Hartmut Kabisch",
year = "2011",
language = "English",
volume = "38",
pages = "1307--1317",
journal = "INT J ONCOL",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

RIS

TY - JOUR

T1 - SV40 and p53 as team players in childhood lymphoproliferative disorders.

AU - Heinsohn, Susanne

AU - Scholz, Roswitha

AU - Kabisch, Hartmut

PY - 2011

Y1 - 2011

N2 - Simian virus 40 (SV40) is known to be potently oncogenic and can induce several types of tumours, such as lymphoma. p53 was discovered as a cellular partner of the SV40 large T-antigen, the oncoprotein of this virus. There have not been many studies on SV40 and p53 in lymphomas and the ones that exist, are controversial. A comparison of these two components in lymphoma has not been reported previously. We examined 91 lymphomas [60 B-cell non-Hodgkin's lymphomas (B-NHLs), 19 B-cell acute lymphoblastic leukemias (B-ALLs), 7 B-cell precursor acute lymphoblastic leukemias and 5 T-cell acute lymphoblastic leukemias] for the presence of SV40. Overall, 40 samples from 12 B-NHL/19 B-ALL patients were additionally investigated for p53 mutation in the hot-spot exons 5 to 8. Overall, we found 62/91 lymphomas to be SV40-positive, among them 16/19 B-ALLs and 38/60 B-NHLs. SV40 was absent in 147 of the 149 blood control samples. We found 11 p53 mutations in 19 B-ALL patients: 5 in exon 5 (codons 132, 141, 143, 155 and 181), 4 in exon 7 (codons 236, 238 and 248), 2 in exon 8 (codon 273). In B-NHL patients we found p53-mutations in 9/12 samples: 6 of these in 3 lymph nodes (LNs). One LN harboured 3 different p53 mutations: Exon 5 (codon 132), exon 6 (codon 213) and exon 8 (codon 288). Another LN showed 2 different p53 mutations: Exon 6 (codon 213) and exon 8 (codon 285). Except for 1 nonsense mutation in an LN of a B-NHL patient, all 20 mutations were missense mutations, 2 were homozygous, both found in B-NHL-samples, and one of these (codon 175) is known to cause the global denaturation of p53. All occur in the DNA-binding domain of p53. All specimens showing a p53 mutation, were SV40-positive. p53 mutaions found in LNs of B-NHL patients harbour high SV40 copy numbers. Our data strongly support an important role for SV40, as well as a strong association of SV40 and p53 in childhood lympho-proliferative disorders.

AB - Simian virus 40 (SV40) is known to be potently oncogenic and can induce several types of tumours, such as lymphoma. p53 was discovered as a cellular partner of the SV40 large T-antigen, the oncoprotein of this virus. There have not been many studies on SV40 and p53 in lymphomas and the ones that exist, are controversial. A comparison of these two components in lymphoma has not been reported previously. We examined 91 lymphomas [60 B-cell non-Hodgkin's lymphomas (B-NHLs), 19 B-cell acute lymphoblastic leukemias (B-ALLs), 7 B-cell precursor acute lymphoblastic leukemias and 5 T-cell acute lymphoblastic leukemias] for the presence of SV40. Overall, 40 samples from 12 B-NHL/19 B-ALL patients were additionally investigated for p53 mutation in the hot-spot exons 5 to 8. Overall, we found 62/91 lymphomas to be SV40-positive, among them 16/19 B-ALLs and 38/60 B-NHLs. SV40 was absent in 147 of the 149 blood control samples. We found 11 p53 mutations in 19 B-ALL patients: 5 in exon 5 (codons 132, 141, 143, 155 and 181), 4 in exon 7 (codons 236, 238 and 248), 2 in exon 8 (codon 273). In B-NHL patients we found p53-mutations in 9/12 samples: 6 of these in 3 lymph nodes (LNs). One LN harboured 3 different p53 mutations: Exon 5 (codon 132), exon 6 (codon 213) and exon 8 (codon 288). Another LN showed 2 different p53 mutations: Exon 6 (codon 213) and exon 8 (codon 285). Except for 1 nonsense mutation in an LN of a B-NHL patient, all 20 mutations were missense mutations, 2 were homozygous, both found in B-NHL-samples, and one of these (codon 175) is known to cause the global denaturation of p53. All occur in the DNA-binding domain of p53. All specimens showing a p53 mutation, were SV40-positive. p53 mutaions found in LNs of B-NHL patients harbour high SV40 copy numbers. Our data strongly support an important role for SV40, as well as a strong association of SV40 and p53 in childhood lympho-proliferative disorders.

KW - Animals

KW - Humans

KW - Adolescent

KW - Child

KW - Child, Preschool

KW - Infant

KW - Infant, Newborn

KW - COS Cells

KW - Cercopithecus aethiops

KW - Exons

KW - Mutation

KW - Genes, p53/physiology

KW - Lymphoproliferative Disorders/etiology/genetics/virology

KW - Simian virus 40/isolation & purification

KW - Animals

KW - Humans

KW - Adolescent

KW - Child

KW - Child, Preschool

KW - Infant

KW - Infant, Newborn

KW - COS Cells

KW - Cercopithecus aethiops

KW - Exons

KW - Mutation

KW - Genes, p53/physiology

KW - Lymphoproliferative Disorders/etiology/genetics/virology

KW - Simian virus 40/isolation & purification

M3 - SCORING: Journal article

VL - 38

SP - 1307

EP - 1317

JO - INT J ONCOL

JF - INT J ONCOL

SN - 1019-6439

IS - 5

M1 - 5

ER -